TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05549947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group D：placebo
Study: NCT06148402
Drug: Fruquintinib plus camrelizumab and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
Study: NCT04924166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive dose of capsules that appear identical to active dose
Study: NCT04924166
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 180 mg in capsule form
Study: NCT06077669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo
Study: NCT05891834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, once daily, oral
Study: NCT05683886
Drug: KC1036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
Study: NCT05370547
Drug: Fludarabine and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m\^2) and cyclophosphamide (250-500 mg/m\^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
Study: NCT06641037
Drug: LY3866288
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06113328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator to MK-6194 administered SC
Study: NCT04882072
Drug: Glucorticoid Taper Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid will be administered orally.
Study: NCT05632809
Drug: NKTR-255
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT04750577
Drug: Placebo matching BI 685509
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablet
Study: NCT05957302
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
Study: NCT04935762
Drug: CST-103, CST-107, matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
Study: NCT06340360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Study: NCT05213624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 764198
Study: NCT05059535
Drug: standard pain relievers
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
Study: NCT06116890
Drug: KHK4951
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK4951 eye drop for 44 weeks until end of the trial
Study: NCT06058013
Drug: NMRA-335140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Study: NCT06058013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally
Study: NCT06309485
Drug: WGI-0301 at MTD/RP2D dose IV infusion, QW
Approvals — FDA: no, EMA: no, PMDA: no
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
Study: NCT06309485
Drug: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW
Approvals — FDA: no, EMA: no, PMDA: no
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
Study: NCT05701774
Drug: DCCR
Normalized name: Diazoxide Choline Controlled-Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral administration
Study: NCT05717062
Drug: Placebo intravenous form
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
Study: NCT05717062
Drug: Placebo - oral form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
Study: NCT06209047
Drug: bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
Study: NCT05600894
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06562192
Drug: [177Lu]Lu-NNS309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand therapy
Study: NCT05288777
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
Study: NCT05881135
Drug: Saline/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administered every 12 hours as a 10 ml bolus for 5 days.
Study: NCT06481891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
Study: NCT06502964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo patches
Study: NCT05093959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
Study: NCT04802057
Drug: SAR445088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: IV and SC (Part 1) IV (Part 2)
Study: NCT05307692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally as a tablet.
Study: NCT05421858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for caspofungin (IV infusion)
Study: NCT05677490
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05677490
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06545500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by a standard jet nebulizer, twice daily for 7 consecutive days
Study: NCT05172518
Drug: Taxane plus Intermittent Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study: NCT05172518
Drug: Utidelone plus Intermittent Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study: NCT05172518
Drug: Taxane plus Metronomic Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study: NCT05172518
Drug: Utidelone plus Metronomic Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study: NCT05894148
Drug: Genakumab injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 120mg Q4W，group 2: 200mg Q4W
Study: NCT05894148
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
Study: NCT04673357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as SC injection.
Study: NCT05653349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, prepared from matching placebo
Study: NCT05653349
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or parental (if clinically justified)
Study: NCT04929210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as subcutaneous injection.
Study: NCT06527222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine placebo twice daily
Study: NCT06647953
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06647953
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06679205
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
Study: NCT05169567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05848713
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement.
Study: NCT06572449
Drug: KarXT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06731764
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily.
Study: NCT06731764
Drug: Levothyroxine/Liothyronine once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;
Study: NCT06523725
Drug: PO BRC-003 (High Cannabidiol Cannabis Extract)
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B).
Study: NCT06523725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04673799
Drug: MV088 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: MV088 injection (60mg) by subcutaneous injection once on the first day
Study: NCT04673799
Drug: Prolia® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolia® injection (60mg) by subcutaneous injection once on the first day
Study: NCT05552274
Drug: ECC4703
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.
Study: NCT05552274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
Study: NCT06347770
Drug: Probiotic Blend Oral Tablet
Normalized name: Probiotic Blend Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
Study: NCT04968912
Drug: Standard of Care Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
Study: NCT05844930
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone 20 mg (1cc)
Study: NCT04582669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
Study: NCT06358430
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05454332
Drug: Early Caffeine administration
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
Study: NCT05635318
Drug: FDA approved medications for ADHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
Study: NCT04857047
Drug: BR9003 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
Study: NCT04857047
Drug: BR9003A 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
Study: NCT04906590
Drug: [18F] PI-2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
Study: NCT05857514
Drug: Rectal Indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
Study: NCT06479122
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g acetaminophen is administered during skin closure (end of operation).
Study: NCT06479122
Drug: Acetaminophen/Ibuprofen
Normalized name: ACETAMINOPHEN/IBUPROFEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)
Study: NCT06479122
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g acetaminophen is administered 6 hours after the first administration.
Study: NCT06479122
Drug: Acetaminophen/Ibuprofen
Normalized name: ACETAMINOPHEN/IBUPROFEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
Study: NCT03338764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
Study: NCT04519983
Drug: Aumolertinib Oral Tablet
Normalized name: aumolertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aumolertinib 110 mg p.o. qd+ SRT(32Gy/4fx)
Study: NCT04291703
Drug: Placebo (for ATG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline administered by IV infusion to mimic ATG
Study: NCT06077877
Drug: GSK4524101
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK452101 will be administered.
Study: NCT05535218
Drug: Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment: 7,5mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant).
Study: NCT06449469
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
Study: NCT04082481
Drug: TAK-988 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-988 placebo-matching tablets.
Study: NCT06151847
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06424288
Drug: vicadrostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicadrostat
Study: NCT06424288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 690517
Study: NCT05692271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05242484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as subcutaneous injection.
Study: NCT05521048
Drug: Doxycycline Injection [Doxy]
Normalized name: doxycycline Injection [Doxy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
Study: NCT05482334
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriostatic Saline
Study: NCT04489589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg PO/NG q8h